• CLPBY
• COLOb

UBS revises Coloplast rating to 'neutral,' sees lower risk

UBS upgraded Coloplast to 'neutral' from 'sell,' citing reduced competitive concerns and stable growth projections amid favorable market adjustments and a realistic stock valuation.